This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

11 Mar 2011

Epizyme & Eisai Partner for Epigenetic Enzyme

Epizyme Inc. has partnered with Japanese firm Eisai Co. Ltd. to prompt development and commercialization of new treatments aimed at epigenetic enzyme.

Epizyme, Inc. has announced a partnership with Eisai Co. to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers.


Under the agreement, Epizyme will receive $6 million upfront and is eligible to receive more than $200 million in additional R&D and sales milestones, as well as royalties. Eisai will fund all research through human proof-of-concept, at which point Epizyme can opt into a profit share and co-commercialization agreement in the U.S.

"Eisai is committed to bringing epigenetic therapeutics to cancer patients,” said Takashi Owa, Ph.D., president, Onc

Related News